A service evaluation comparing CVVH an CVVHD in minimising circuit failure
- PMID: 26871268
- DOI: 10.1111/nicc.12230
A service evaluation comparing CVVH an CVVHD in minimising circuit failure
Erratum in
-
Erratum.Nurs Crit Care. 2017 May;22(3):186. doi: 10.1111/nicc.12291. Nurs Crit Care. 2017. PMID: 28444718 No abstract available.
Abstract
Background: A significant problem during continuous renal replacement therapy is premature circuit failure, affecting efficacy and molecular clearance. Techniques to improve circuit failure are anticoagulation, access site and modality. A modality change was introduced, moving from continuous veno-venous haemofiltration to continuous veno-venous haemodiafiltration as a result of existing issues with failing circuit times and failure rates.
Aim: The aim of this service evaluation was to ascertain if the use of continuous veno-venous haemodiafiltration compared to continuous veno-venous haemofiltration had affected failed circuit survival times and rates.
Methods: A service evaluation was chosen because the focus was to ascertain what effect a practice change had had on a particular service. The service evaluation was registered with the local trust's audit department and gained university ethical approval. It was anticipated that the data generated would be used to inform, question and improve practices. Patients who received renal replacement therapy (RRT) from May 2012 to January 2013 were retrospectively identified. Patients received continuous veno-venous haemofiltration for the duration of their treatment before September 2012 and continuous veno-venous haemodiafiltration after. A total of 78 patients were identified as receiving RRT; 41 of these patients had failed circuits.
Results: A total of 182 failed circuits were analysed. The median duration of failed circuits during continuous veno-venous haemofiltration was shorter (2·75 h, standard deviation (SD) = 13·82) when compared to continuous veno-venous haemodiafiltration (11 h, SD = 15·26, p < 0·001, 95% confidence interval (CI) 2·5-10). Circuit failure rate in continuous veno-venous haemofiltration was 56% compared to 43% in continuous veno-venous haemodiafiltration. After performing a Cox regression analysis, continuous veno-venous haemofiltration appeared to have a 1·87 times (CI 1·18-2·82, p > 0·007) more likely chance of failure.
Conclusion: The use of continuous veno-venous haemodiafiltration has had an overall positive effect on the haemofiltration service by reducing the number of failed circuits and increasing circuit survival times, which may have improved the efficacy of the service. Continuous veno-venous haemodiafiltration may be a more appropriate modality of choice in non-septic patients requiring prolonged continuous RRT episodes.
Keywords: CRRT; CVVH; CVVHDF; circuit; failure; results.
© 2016 British Association of Critical Care Nurses.
Similar articles
-
Influence of continuous veno-venous haemodiafiltration and continuous veno-venous haemofiltration on the pharmacokinetics of fluconazole.Eur J Clin Pharmacol. 2000 Dec;56(9-10):671-8. doi: 10.1007/s002280000216. Eur J Clin Pharmacol. 2000. PMID: 11214774 Clinical Trial.
-
Elimination of meropenem during continuous veno-venous haemofiltration and haemodiafiltration in patients with acute renal failure.J Antimicrob Chemother. 2000 May;45(5):701-4. doi: 10.1093/jac/45.5.701. J Antimicrob Chemother. 2000. PMID: 10797097
-
Low Blood Flow Continuous Veno-Venous Haemodialysis Compared with Higher Blood Flow Continuous Veno-Venous Haemodiafiltration: Effect on Alarm Rates, Filter Life, and Azotaemic Control.Blood Purif. 2022;51(2):130-137. doi: 10.1159/000516146. Epub 2021 May 19. Blood Purif. 2022. PMID: 34010832
-
Replacement and dialysate fluids for patients with acute renal failure treated by continuous veno-venous haemofiltration and/or haemodiafiltration.Contrib Nephrol. 2004;144:317-28. doi: 10.1159/000078899. Contrib Nephrol. 2004. PMID: 15264420 Review. No abstract available.
-
Dosage adjustment of fluconazole during continuous renal replacement therapy (CAVH, CVVH, CAVHD, CVVHD).Mycoses. 1999 Apr;42(1-2):17-9. doi: 10.1046/j.1439-0507.1999.00269.x. Mycoses. 1999. PMID: 10394842 Review.
Cited by
-
Non anti-coagulant factors associated with filter life in continuous renal replacement therapy (CRRT): a systematic review and meta-analysis.BMC Nephrol. 2017 Feb 20;18(1):69. doi: 10.1186/s12882-017-0445-5. BMC Nephrol. 2017. PMID: 28219324 Free PMC article.
-
Coagulation Risk Predicting in Anticoagulant-Free Continuous Renal Replacement Therapy.Blood Purif. 2024;53(11-12):916-927. doi: 10.1159/000540695. Epub 2024 Aug 12. Blood Purif. 2024. PMID: 39134011 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources